Shares of ImmunityBio, Inc. (NASDAQ:IBRX - Get Free Report) were down 4.2% on Thursday . The stock traded as low as $7.73 and last traded at $7.76. Approximately 1,968,418 shares were traded during mid-day trading, a decline of 67% from the average daily volume of 6,010,044 shares. The stock had previously closed at $8.10.
Analyst Upgrades and Downgrades
Separately, Piper Sandler upped their target price on ImmunityBio from $5.00 to $6.00 and gave the company a "neutral" rating in a research report on Monday, April 29th.
Read Our Latest Stock Analysis on IBRX
ImmunityBio Stock Performance
The firm's 50 day moving average price is $6.22 and its two-hundred day moving average price is $4.83. The company has a market cap of $5.36 billion, a P/E ratio of -7.43 and a beta of 1.16.
ImmunityBio (NASDAQ:IBRX - Get Free Report) last posted its quarterly earnings results on Tuesday, March 19th. The company reported ($0.19) earnings per share for the quarter, missing the consensus estimate of ($0.18) by ($0.01). The business had revenue of $0.14 million for the quarter, compared to analysts' expectations of $0.03 million. As a group, analysts forecast that ImmunityBio, Inc. will post -0.75 EPS for the current fiscal year.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Vanguard Group Inc. raised its position in shares of ImmunityBio by 42.0% during the third quarter. Vanguard Group Inc. now owns 14,675,687 shares of the company's stock worth $24,802,000 after purchasing an additional 4,342,386 shares during the period. Armistice Capital LLC bought a new stake in shares of ImmunityBio during the third quarter worth about $5,874,000. Stratos Wealth Partners LTD. acquired a new stake in shares of ImmunityBio in the 4th quarter worth about $171,000. SG Americas Securities LLC lifted its position in ImmunityBio by 45.4% in the 4th quarter. SG Americas Securities LLC now owns 49,005 shares of the company's stock valued at $246,000 after acquiring an additional 15,308 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in ImmunityBio by 46.6% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 28,105 shares of the company's stock valued at $141,000 after purchasing an additional 8,932 shares during the last quarter. Institutional investors own 8.58% of the company's stock.
ImmunityBio Company Profile
(
Get Free Report)
ImmunityBio, Inc, a clinical-stage biotechnology company, engages in discovering, developing, and commercializing next-generation immuno- and cellular therapies for cancer and infectious diseases in the United States and Europe. The company offers immunotherapy and cell therapy platforms, including antibody cytokine fusion protein N-803, vaccine delivery technologies, and natural killer cell therapies.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider ImmunityBio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ImmunityBio wasn't on the list.
While ImmunityBio currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.
Get This Free Report
